Comparative analysis of T-cell depletion method for clinical immunotherapy-anti-hepatitis c effects of natural killer cells via interferon-γ production (Q50906319)

From Wikidata

Jump to navigation Jump to search

scientific article published in June 2013

Language	Label	Description	Also known as
English	Comparative analysis of T-cell depletion method for clinical immunotherapy-anti-hepatitis c effects of natural killer cells via interferon-γ production	scientific article published in June 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23769105

Comparative analysis of T-cell depletion method for clinical immunotherapy-anti-hepatitis c effects of natural killer cells via interferon-γ production (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23769105

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23769105

Andreas G. Tzakis

13

object named as

A G Tzakis

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

Camillo Ricordi

11

object named as

C Ricordi

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

12

object named as

H Ohdan

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23769105

author name string

S Nishida

2

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23769105

T Matsuura

3

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23769105

I Muraoka

4

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23769105

P Tryphonopoulos

5

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23769105

J Fan

6

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23769105

A Tekin

7

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23769105

G Selvaggi

8

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23769105

D Levi

9

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23769105

P Ruiz

10

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23769105

language of work or name

0 references

publication date

1 June 2013

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23769105

Transplantation Proceedings

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23769105

45

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23769105

5

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23769105

2045-2050

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23769105

Liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease era.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Early recurrence of hepatitis C virus infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Hepatitis C and liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Hepatic transplant and HCV: a new playground for an old virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Biology of natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

The liver as a crucial organ in the first line of host defense: the roles of Kupffer cells, natural killer (NK) cells and NK1.1 Ag+ T cells in T helper 1 immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Impact of adjuvant immunotherapy using liver allograft-derived lymphocytes on bacteremia in living-donor liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Clinical-scale isolation of interleukin-2-stimulated liver natural killer cells for treatment of liver transplantation with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Possibility of adoptive immunotherapy with peripheral blood-derived CD3⁻CD56+ and CD3+CD56+ cells for inducing antihepatocellular carcinoma and antihepatitis C virus activity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone-marrow transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Donor leukocyte infusions in acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells?

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Effect of alpha interferon on the hepatitis C virus replicon

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Binding of thymoglobulin to natural killer cells leads to cell activation and interferon-gamma production

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2013.01.046

7 January 2021

Identifiers

10.1016/J.TRANSPROCEED.2013.01.046

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23769105

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23769105

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50906319&oldid=2263098190"